ClinicalTrials.gg
Active, not recruitingNCT05101460Updated Apr 21, 2026

An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant

An observational study in Lung Transplant, sponsored by XVIVO Perfusion. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by XVIVO Perfusion · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
315
Ages
18 Years and older
Sex
All
01

Study summary

The XVIVO Registry is to collect standard of care clinical data from "all-comers" who are transplanted with an EVLP lung treated with the XVIVO Perfusion System™ in order to assess the long-term performance of the device, and monitor device-related serious adverse events. In addition, 4 and 5-year UNOS registry data of the 126 subjects who received an EVLP transplant under the NOVEL and NOVEL Extension studies are provided as part of the long-term safety and quality of life data. In addition, 4 and 5-year UNOS registry data of the 126 subjects who received an EVLP transplant under the NOVEL and NOVEL Extension studies are provided as part of the long-term safety and quality of life data.

Read the detailed description

The XVIVO registry is an ongoing, observational, multicenter, retrospective review of patients exposed to XPS™ EVLP-treated lungs. The Registry study is aligned and managed by the UNOS and OPTN data collection process. This registry uses quarterly STAR file data requests for the OPTN data managed by UNOS.

The EVLP procedure and transplantation will be performed per XPS™ Instructions for Use and the treating physician's discretion. Post-transplant clinical care will follow the institution's standard-of-care policies.

OPTN updated the data collected since the submission of the protocol therefore the data collection has changed. The following data has updated collection:

  • Collects if hospitalized since last follow-up (yes, no), not the number of hospitalizations
  • Collects acute rejection episodes (yes treated, yes not treated, no), not the number of episodes
  • Collects Karnofsky Score as replacement for Physical and functional capacity
  • Employment limitations has been updated to working for income (yes or no)
  • No longer collects BOS, XVIVO to request BOS evaluations on subjects with visits prior to June 30, 2020 and any other omissions of end points not available in the data requested via STAR request.
  • Collects FEV1 (L) effective June 30, 2020 to calculate CLAD and diagnosis of CLAD, if applicable.
  • No longer provides Other, Specify text in STAR request.
02

Conditions studied

  • Lung Transplant

Keywords

  • Lung Transplant; Transplantation lung
03

In context

Lead sponsor

XVIVO Perfusion is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

This is an "All Comers Registry" hence, no specific investigator sites. All patients receiving EVLP lungs treated with XPS™ will be included in the registry without eligibility criteria or pre-selection. Since the registry collects only standard-of-care data and requires no additional procedures or risks to the subject, a waiver of consent is appropriate

Eligibility criteria

This is an "All Comers Registry" hence will include all patients receiving EVLP lungs.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
315 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Interventions

  • DeviceXVIVO Perfusion System (XPS™) with STEEN Solution™

    XVIVO Perfusion System (XPS™) with STEEN Solution™

06

What researchers measure

Primary outcomes

  1. Survival at 1 year post-transplant

    Primary effectiveness endpoint

    Time frame: 12 months

  2. Primary Graft Dysfunction (PGD)

    Rate of Grade 3 Primary Graft Dysfunction (PGD) at 72 hours

    Time frame: 72 hours

Secondary outcomes

  1. Post-transplant survival

    Survival at 2, 3, 4 and 5 years post-transplant

    Time frame: 2 years, 3 years, 4 years and 5 years post-transplant

  2. Pulmonary Function Test (FEV1)

    Pulmonary Function Test (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEV1 is the key lung function test in diagnosing BOS. FEV1 test at 1 year, 2 years, 3 years, 4 years and 5 years post-transplant.

    Time frame: 1 year, 2 years, 3 years, 4 years and 5 years post-transplant

  3. Incidence of Bronchiolitis Obliterans Syndrome (BOS) or Chronic Lung Allograft Dysfunction (CLAD)

    Rate of Grade 0 through 3 Bronchiolitis Obliterans Syndrome (BOS) at 1 year, 2 years, 3 years, 4 years and 5 years post-transplant. Clinically, BOS is associated with a progressive decline in forced expiratory volume in one second (FEV1) greater than or equal to 20% of baseline. Decline in FEV1 % increases the risk of development of BOS (Grade 0 to 3). CLAD is defined as a substantial and persistent decline (≥ 20%) in measured FEV1 value from the reference (baseline) value after lung transplantation, with or without a change in FVC. If CLAD is identified, staging and phenotype will be assigned.

    Time frame: 1 year, 2 years, 3 years, 4 years and 5 years post-transplant

  4. Hospitalizations

    The presence of in-patient hospital admissions between transplant and 1 year, 1-2 years, 2-3 years, 3-4 years, and 4-5 years post-transplant

    Time frame: 1 year, 2 years, 3 years, 4 years and 5 years post-transplant

  5. Acute Rejection Episodes

    The presence of biopsy proven hospital admissions between transplant and 1 year, 1-2 years, 2-3 years, 3-4 years, and 4-5 years post-transplant

    Time frame: 1 year, 1-2 years, 2-3 years, 3-4 years, and 4-5 years post-transplant

  6. Karnofsky Performance Status Scale (KPS)/Karnofsky score

    Karnofsky Performance Status Scale is an assessment tool for functional impairment. It is used to improve understanding of patient needs, ability to carry out daily activities and to assess patient prognosis. Karnofsky score is calculated at 1 year, 2 years, 3 years, 4 years and 5 years post-transplant. Higher the Karnofsky score, better the ability to carry out daily activities.

    Time frame: 1 year, 2 years, 3 years, 4 years and 5 years post-transplant

  7. Safety Endpoint

    XPS related SAEs from transplant to 30 days post-transplant or initial hospital stay, whichever is longer

    Time frame: 30 days post-transplant

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2019 (actual). Primary completion is estimated for Apr 2029, 113 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2021
First posted
Nov 1, 2021
StartActual
Oct 29, 2019
Primary completionEst.
Apr 24, 2029
CompletionEst.
Apr 24, 2029
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05101460
Lead sponsor
XVIVO Perfusion
Responsible party
Sponsor
First posted
Nov 1, 2021
Start date
Oct 29, 2019
Primary completion
Apr 24, 2029 (estimated)
Completion
Apr 24, 2029 (estimated)
Last update
Apr 21, 2026

Study contacts

Sarah Lowe
study director · XVIVO Perfusion

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion